Ketamine for Endometriosis Pain

Overseen By Vaishali Shah

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: NYU Langone Health

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing whether a small dose of ketamine can help reduce pain after surgery in women with chronic pelvic pain from endometriosis. Ketamine works by blocking pain signals in the brain. Ketamine is an old anesthetic agent that has been explored for its efficacy in treating various pain conditions, including chronic pain and postoperative pain.

Research Team

Kathy Huang, MD

Principal Investigator

NYU Langone Health

Eligibility Criteria

This trial is for adult women aged 18-65 with chronic pelvic pain who are scheduled for robotic endometriosis removal surgery. Participants should be medically stable and willing to follow the study procedures throughout its duration.

Inclusion Criteria

I am scheduled for a robotic surgery to remove endometriosis.

You are in good overall health.

I am between 18 and 65 years old.

Treatment Details

Interventions

• Ketamine (NMDA Receptor Antagonist)
• Placebo (Behavioural Intervention)

Trial Overview The UPKEEP Study tests if a low dose of ketamine (0.6 mg/kg) can better manage postoperative pain compared to a saline placebo in female patients after robotic endometriosis surgery. It's randomized and single-blinded, meaning participants won't know which treatment they receive.

Participant Groups

Group I: Low-Dose Ketamine (LDK) Treatment Group Experimental Treatment 1 Intervention

Group II: Control Group Placebo Group 1 Intervention

Ketamine is already approved in Canada for the following indications:

Approved in Canada as Spravato for:

• Treatment-resistant depression

Who Is Running the Clinical Trial?

NYU Langone Health

Lead Sponsor

Trials

1,431

Recruited

838,000+